AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19056661 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin and selenium supplementation for 7.3 years
Number of subjects: 3411
Study 19056661 — intervention group
Group type: COMPARATOR
Intervention: Anti-H. pylori treatment with amoxicillin (1 g twice daily) and omeprazole (20 mg twice daily)
Number of subjects: 3411
Study 19056661 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B-12 and homocysteine levels
Number of subjects: 3411
Study 17908276 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-controlled MMF dosing
Number of subjects: 137
Study 17908276 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose MMF
Number of subjects: 137
Study 15036828 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 1 component of metabolic syndrome
Number of subjects: 6182
Study 15036828 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 2 components of metabolic syndrome
Number of subjects: 6182
Study 15036828 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 3 components of metabolic syndrome
Number of subjects: 6182
Study 15036828 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 4 or more components of metabolic syndrome
Number of subjects: 6182
Study 11751658 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL 12.5 mg once daily
Number of subjects: 14
Study 11751658 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL titrated to 200 mg once daily
Number of subjects: 14
Study 9428538 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at 5 ppm
Number of subjects: 177
Study 9428538 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrogen gas)
Number of subjects: 177
Study 9428538 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO)
Number of subjects: 177
Study 8116033 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intravenous immunoglobulin (IVIG; 0.5 g/kg) for 6 doses and oral acyclovir for 3 months
Number of subjects: 82
Study 8116033 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (2.5 mg/kg) twice daily for 2 weeks followed by oral acyclovir for 3 months
Number of subjects: 82
Study 8116033 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogam (100-150 mg/kg) plus 2 weeks of i.v. ganciclovir followed by 3 months of oral acyclovir
Number of subjects: 82
Study 8116033 — intervention group
Group type: COMPARATOR
Intervention: Standard IVIG (5 doses over 2 months)
Number of subjects: 82
Study 30286025 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy for patients with locally advanced disease
Number of subjects: 0
Study 30286025 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective use of radiation in the context of the PROSPECT randomized controlled trial
Number of subjects: 0
Study 30286025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management in the context of the Organ Preservation in Rectal Adenocarcinoma trial
Number of subjects: 0
Study 28586510 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐s maximum‐effort sprint
Number of subjects: 9
Study 28586510 — intervention group
Group type: COMPARATOR
Intervention: 10‐s rest
Number of subjects: 9
Study 26202994 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Articaine (A2)
Number of subjects: 46
Study 26202994 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% Articaine (A4)
Number of subjects: 46
Study 24261013 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport education classes
Number of subjects: 6
Study 24261013 — intervention group
Group type: COMPARATOR
Intervention: Traditional teacher-directed format
Number of subjects: 6
Study 21979399 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic colon preparation (10 ounces of magnesium citrate 2 days prior, followed by 10 ounces of magnesium citrate and 4-L polyethylene glycol the day prior)
Number of subjects: 198
Study 21979399 — intervention group
Group type: COMPARATOR
Intervention: Standard colon preparation (10 ounces of magnesium citrate and 4-L polyethylene glycol the day prior)
Number of subjects: 198
Study 19819612 — intervention group
Group type: EXPERIMENTAL
Intervention: Doorstep canvassing by trained canvassers
Number of subjects: 194
Study 19819612 — intervention group
Group type: COMPARATOR
Intervention: Control group (no canvassing)
Number of subjects: 194
Study 16822111 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session intervention focusing on Internet information consumer skills
Number of subjects: 448
Study 16822111 — intervention group
Group type: COMPARATOR
Intervention: Time-matched support group
Number of subjects: 448
Study 12587892 — intervention group
Group type: EXPERIMENTAL
Intervention: Bungy squat jumps
Number of subjects: 0
Study 12587892 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-bungy squat jumps
Number of subjects: 0
Study 12587892 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10918990 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate whey hydrolysate formula (pHF, Nestlé Beba HA) and breastfeeding, with no weaning food before 4 months of age (Z cohort, n = 564)
Number of subjects: 1130
Study 10918990 — intervention group
Group type: COMPARATOR
Intervention: No intervention (FF cohort, n = 566)
Number of subjects: 1130
Study 9051332 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (100 micrograms)
Number of subjects: 0
Study 9051332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 8266005 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion
Number of subjects: 18
Study 3488385 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethyl succinate
Number of subjects: 170
Study 3488385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 30092768 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational leaflet explaining symptoms of gynaecological cancers
Number of subjects: 15538
Study 30092768 — intervention group
Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 15538
Study 27813503 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium, paracetamol and pamabrom
Number of subjects: 189
Study 27813503 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol, pyrilamine and pamabrom
Number of subjects: 189
Study 23633128 — intervention group
Group type: EXPERIMENTAL
Intervention: D-mannose powder (2 g in 200 ml of water daily for 6 months)
Number of subjects: 308
Study 23633128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (50 mg daily)
Number of subjects: 308
Study 23633128 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 308
Study 22581047 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal phacoemulsification
Number of subjects: 405
Study 22581047 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal SICS
Number of subjects: 405
Study 20034729 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG
Number of subjects: 957
Study 20034729 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 957
Study 18619113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen narcosis
Number of subjects: 62
Study 18619113 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.5 g/kg dose)
Number of subjects: 62
Study 18619113 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 62
Study 15984978 — intervention group
Group type: EXPERIMENTAL
Intervention: VSL#3, 3,600 billion bacteria daily in two divided doses for 6 weeks
Number of subjects: 34
Study 12461219 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management
Number of subjects: 146
Study 12461219 — intervention group
Group type: COMPARATOR
Intervention: Standard case management
Number of subjects: 146
Study 10515442 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril for 12 weeks (Period I)
Number of subjects: 489
Study 10515442 — intervention group
Group type: COMPARATOR
Intervention: Enalapril for 12 weeks (Period I)
Number of subjects: 489
Study 8821078 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa medication
Number of subjects: 12
Study 8821078 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of L-Dopa
Number of subjects: 12
Study 2026989 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 33
Study 2026989 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 33
Study 7294616 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (Healon) used during IOL implantation
Number of subjects: 20
Study 7294616 — intervention group
Group type: COMPARATOR
Intervention: Conventional IOL implantation (Control)
Number of subjects: 20
Study 31454432 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS)
Number of subjects: 101
Study 31454432 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy with interval debulking
Number of subjects: 101
Study 29471922 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach bias modification (ApBM)
Number of subjects: 33
Study 29471922 — intervention group
Group type: COMPARATOR
Intervention: Sham-Approach bias modification (sham-ApBM)
Number of subjects: 33
Study 26906704 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic made aspheric intraocular lens (Model: A1-UV)
Number of subjects: 119
Study 26906704 — intervention group
Group type: COMPARATOR
Intervention: Imported aspheric intraocular lens (Model: SN60WF)
Number of subjects: 119
Study 24490769 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafts (CABG)
Number of subjects: 0
Study 24490769 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 0
Study 24490769 — intervention group
Group type: COMPARATOR
Intervention: First generation drug-eluting stents
Number of subjects: 0
Study 24490769 — intervention group
Group type: COMPARATOR
Intervention: Latest generation drug-eluting stents
Number of subjects: 0
Study 22904010 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomechanical evidence presented at sentencing
Number of subjects: 181
Study 22904010 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical case without biomechanical evidence
Number of subjects: 181
Study 20451404 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) 75 mg/m² subcutaneously for 7 days every 28 days (n=38)
Number of subjects: 87
Study 20451404 — intervention group
Group type: COMPARATOR
Intervention: Conventional care regimens (CCR) (n=49)
Number of subjects: 87
Study 20451404 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Number of subjects: 87
Study 20451404 — intervention group
Group type: COMPARATOR
Intervention: Conventional care regimens (CCR)
Number of subjects: 87
Study 17548850 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program
Number of subjects: 84
Study 17548850 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 84
Study 16103896 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 2735
Study 16103896 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin, Lovastatin, Pravastatin, Simvastatin
Number of subjects: 2735
Study 12370520 — intervention group
Group type: EXPERIMENTAL
Intervention: NNRTI-containing regimens initiated in patients with hypersusceptibility (n = 21)
Number of subjects: 177
Study 12370520 — intervention group
Group type: COMPARATOR
Intervention: NNRTI-containing regimens initiated in patients without hypersusceptibility (n = 77)
Number of subjects: 177
Study 12370520 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypersusceptible virus
Number of subjects: 177
Study 12370520 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypersusceptibility to NNRTI
Number of subjects: 177
Study 10193975 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg twice daily
Number of subjects: 99
Study 10193975 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 250 mg twice daily
Number of subjects: 99
Study 10193975 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with a positive history of oral herpes labialis)
Number of subjects: 99
Study 10193975 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without a known HSV history)
Number of subjects: 99
Study 7572006 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.3 microgram/kg body weight)
Number of subjects: 79
Study 7572006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 2271467 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (subclavian perivascular injection after withdrawing from the artery)
Number of subjects: 18
Study 2271467 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (subclavian perivascular injection after advancing through the artery)
Number of subjects: 18
Study 7270401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prenalterol (PNL) 75 to 225 microgram/kg
Number of subjects: 8
Study 7270401 — intervention group
Group type: COMPARATOR
Intervention: Intravenous prenalterol (PNL) during exercise
Number of subjects: 8
Study 7270401 — intervention group
Group type: COMPARATOR
Intervention: Oral prenalterol (PNL) 30 to 200 mg/day
Number of subjects: 8
Study 7270401 — intervention group
Group type: COMPARATOR
Intervention: Oral prenalterol (PNL) vs placebo
Number of subjects: 8
Study 31764465 — intervention group
Group type: EXPERIMENTAL
Intervention: WALK3 (30-min sitting/3-min brisk treadmill walk)
Number of subjects: 16
Study 31764465 — intervention group
Group type: EXPERIMENTAL
Intervention: WALK5 (45-min sitting/5-min brisk treadmill walk)
Number of subjects: 16
Study 31764465 — intervention group
Group type: EXPERIMENTAL
Intervention: WALK8 (60-min sitting/8-min brisk treadmill walk)
Number of subjects: 16
Study 31764465 — intervention group
Group type: COMPARATOR
Intervention: SIT (9-h uninterrupted sitting)
Number of subjects: 16
Study 30348198 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill gait training plus visual feedback (+VFB)
Number of subjects: 48
Study 30348198 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking without visual feedback (Control)
Number of subjects: 48
Study 27776992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate enema before urodynamics (group B)
Number of subjects: 139
Study 27776992 — intervention group
Group type: COMPARATOR
Intervention: No enema before urodynamics (group A)
Number of subjects: 139
Study 24231843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin
Number of subjects: 250
Study 24231843 — intervention group
Group type: COMPARATOR
Intervention: Combination of epirubicin and interferon-α2b
Number of subjects: 250
Study 22402068 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART with dietary intervention (diet group, n = 43)
Number of subjects: 83
Study 22402068 — intervention group
Group type: COMPARATOR
Intervention: HAART without dietary intervention (control group, n = 40)
Number of subjects: 83
Study 19955052 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 315
Study 18663625 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 163
Study 18663625 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=165)
Number of subjects: 163
Study 16190942 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (1 mg/day)
Number of subjects: 123
Study 16190942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 12772233 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mm length NIR stent in small vessel
Number of subjects: 94
Study 12772233 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mm length NIR stent in small vessel
Number of subjects: 94
Study 12772233 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mm length NIR stent in large vessel
Number of subjects: 94
Study 12772233 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mm length NIR stent in large vessel
Number of subjects: 94
Study 12772233 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 94
Study 10870870 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 288
Study 10870870 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 20 mg/day
Number of subjects: 288
Study 9183341 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin measurement
Number of subjects: 888
Study 9183341 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-glucose insulin measurement
Number of subjects: 888
Study 1581369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 69
Study 1581369 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 69
Study 3853254 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive nursing intervention focusing on assessment of health history, health behaviors, health beliefs, education about CHD risk factors, and methods for detecting and reducing these factors.
Number of subjects: 58
Study 3853254 — intervention group
Group type: COMPARATOR
Intervention: Control group received mailed questionnaires and no intervention.
Number of subjects: 58
Study 3853254 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive nursing intervention
Number of subjects: 58
Study 30861208 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 87
Study 30861208 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee
Number of subjects: 87
Study 29778331 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed perfusion (GDP) strategy during cardiopulmonary bypass (CPB) aimed to maintain oxygen delivery (DO2) at ≥280 mL·min‐1·m‐2
Number of subjects: 350
Study 29778331 — intervention group
Group type: COMPARATOR
Intervention: Conventional perfusion based on body surface area and temperature
Number of subjects: 350
Study 29778331 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed perfusion (GDP) strategy during cardiopulmonary bypass (CPB) for patients with CPB time between 1 and 3 hours
Number of subjects: 350
Study 27260150 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg on day 1, 75 mg on days 2 and 3)
Number of subjects: 10
Study 27260150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 25471907 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical intra-articular TXA (3 g of TXA in 100 mL of physiological saline solution)
Number of subjects: 78
Study 25471907 — intervention group
Group type: COMPARATOR
Intervention: Intravenous TXA (15 mg/kg in 100 mL of physiological saline solution, one dose before tourniquet release and another three hours after surgery)
Number of subjects: 78
Study 25471907 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical intra-articular TXA
Number of subjects: 78
Study 25471907 — intervention group
Group type: COMPARATOR
Intervention: Intravenous TXA
Number of subjects: 78
Study 21999138 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session two-needle arthrocentesis (A)
Number of subjects: 72
Study 21999138 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session two-needle arthrocentesis plus corticosteroid (B)
Number of subjects: 72
Study 21999138 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session two-needle arthrocentesis plus low molecular weight hyaluronic acid (HA) (C)
Number of subjects: 72
Study 21999138 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session two-needle arthrocentesis plus high molecular weight HA (D)
Number of subjects: 72
Study 21999138 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 weekly two-needle arthrocenteses plus low molecular weight HA (E)
Number of subjects: 72
Study 21999138 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 weekly single-needle arthrocenteses plus low molecular weight HA (F)
Number of subjects: 72
Study 20042927 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching (SS)
Number of subjects: 12
Study 20042927 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DS)
Number of subjects: 12
Study 20042927 — intervention group
Group type: COMPARATOR
Intervention: No stretching (NS)
Number of subjects: 12
Study 18388888 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise (treatment group)
Number of subjects: 24
Study 18388888 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 24
Study 15538395 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil transdermal cream (approximately 100 mg containing 300 microg alprostadil) administered by self-insertion into the glans meatus.
Number of subjects: 7
Study 15538395 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil transdermal cream (approximately 100 mg containing 300 microg alprostadil) administered dropwise into the metal opening without touching the penis.
Number of subjects: 7
Study 12874157 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg Chlorella-derived dietary supplement
Number of subjects: 124
Study 12874157 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg Chlorella-derived dietary supplement
Number of subjects: 124
Study 12874157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 10563544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine solution (1.2 mg, pH 4.5)
Number of subjects: 17
Study 10563544 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 17
Study 8671273 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (group A)
Number of subjects: 207
Study 8671273 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching (group B)
Number of subjects: 207
Study 8671273 — intervention group
Group type: COMPARATOR
Intervention: Control group A' (intact zona pellucida)
Number of subjects: 207
Study 8671273 — intervention group
Group type: COMPARATOR
Intervention: Control group B' (intact zona pellucida)
Number of subjects: 207
Study 1681215 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR‐EIA
Number of subjects: 234
Study 1681215 — intervention group
Group type: COMPARATOR
Intervention: DFA
Number of subjects: 234
Study 1681215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular tetracycline treatment
Number of subjects: 234
Study 6496995 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (5.0 mg)
Number of subjects: 30
Study 6496995 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (0.05-0.07 mg/kg)
Number of subjects: 30